Why the study?
Chronic coronary disease is the leading cause of death in the United States, creating an ongoing imperative to align patient care with updated evidence-based guidelines.
This document provides updated AHA/ACC clinical performance and quality measures to align the management of patients with chronic coronary disease with current evidence-based guidelines.
Answers are grounded in this paper and cite their sources.
Enables standardized quality assessment in CCD care; extends AHA/ACC guidelines with actionable performance metrics.
Chronic coronary disease (CCD) is the leading cause of death in the United States. There is an ongoing imperative to disseminate evidence-based and patient-centered care recommendations that further align the management of patients with CCD to updated evidence-based guidelines. The writing committee developed a comprehensive CCD measure set comprising 10 performance measures and 3 quality measures, the focus of which is to include practical steps to specifically advance care in the CCD population. The measure set begins with an assessment of tobacco use and evidence-based cessation interventions. Also included are topics such as antiplatelet therapy, lipid assessment and low-density lipoprotein cholesterol goals, and guideline-directed management and therapy for hypertension and reduced left ventricular dysfunction in patients with CCD. The measure set concludes with an emphasis on the importance of cardiac rehabilitation referral and patient education, including symptom management and lifestyle modification.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: